Senores Pharmaceuticals gets SEBI nod for IPO
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
The acquisition will strengthen the overall company’s position as leading global CRO services partner
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
he company will focus on production of any pharmaceutical and biotechnological products
Developed in consultation with clinicians and patients for an enhanced user experience
Focus on consolidation could help them strengthen their position in the competitive pharmaceutical industry, potentially driving expansion and improving efficiencies
Stable profits, low leverage to keep credit profiles comfortable
Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform
Subscribe To Our Newsletter & Stay Updated